Home›Dabrafenib

Dabrafenib

Route: Oral

8 interactions on record

Dabrafenib has 8 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Itraconazole, Voriconazole, Dexamethasone. Patients taking Dabrafenib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 8
Major: 2
Moderate: 5

Major (2)

Dabrafenib + Itraconazole— Antineoplastics irinotecan axitinib, dabrafenib, dasatinib, ibrutinib, nilotinib, sunitinib bortezomib, busulphan, docet…
Dabrafenib + Voriconazole— Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabr…

Moderate (5)

Dabrafenib + Dexamethasone— Coadministration with dabrafenib can result in decreased concentrations and loss of efficacy. Substitute or monitor for …
Dabrafenib + Gemfibrozil— Gemfibrozil is a strong CYP2C8 inhibitor that may increase dabrafenib exposure; dosing reduction may be required.
Dabrafenib + Midazolam— Dabrafenib decreased systemic exposure of midazolam (CYP3A4 substrate), potentially reducing efficacy. Monitor for loss …
Dabrafenib + Oral Contraceptives— Coadministration with dabrafenib can result in decreased concentrations and loss of efficacy. Substitute or monitor for …
Dabrafenib + Warfarin— Dabrafenib decreased systemic exposure of S-warfarin (CYP2C9 substrate). Monitor INR levels more frequently during initi…

Dabrafenib + Itraconazole⚠️Major

Antineoplastics irinotecan axitinib, dabrafenib, dasatinib, ibrutinib, nilotinib, sunitinib bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, lapatinib, ponatinib, trimetrexate, vinca alkaloids Irinotecan: The potential increase in plasma concentrations of irinotecan when coadministered with itraconazole may increase the risk of potentially fatal adverse events.

Dabrafenib + Voriconazole⚠️Major

Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND.

Dabrafenib + Dexamethasone🟡Moderate

Coadministration with dabrafenib can result in decreased concentrations and loss of efficacy. Substitute or monitor for loss of efficacy if unavoidable.

Dabrafenib + Gemfibrozil🟡Moderate

Gemfibrozil is a strong CYP2C8 inhibitor that may increase dabrafenib exposure; dosing reduction may be required.

Dabrafenib + Midazolam🟡Moderate

Dabrafenib decreased systemic exposure of midazolam (CYP3A4 substrate), potentially reducing efficacy. Monitor for loss of effectiveness.

Dabrafenib + Oral Contraceptives🟡Moderate

Coadministration with dabrafenib can result in decreased concentrations and loss of efficacy. Substitute or monitor for loss of efficacy if unavoidable.

Dabrafenib + Warfarin🟡Moderate

Dabrafenib decreased systemic exposure of S-warfarin (CYP2C9 substrate). Monitor INR levels more frequently during initiation or discontinuation of dabrafenib.

Dabrafenib + Trametinibℹ️Unknown

7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib. Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.